AbbVie Inc (ABBV)vsZymeworks Inc. Common Stock (ZYME)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
ZYME
Zymeworks Inc. Common Stock
$27.83
-0.39%
HEALTHCARE · Cap: $2.07B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 57617% more annual revenue ($61.16B vs $105.97M). ABBV leads profitability with a 6.9% profit margin vs -76.6%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ZYME
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+29.3%
Fair Value
$32.28
Current Price
$27.83
$4.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
No standout strengths identified
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
ROE of -26.7% — below average capital efficiency
Revenue declined 91.9%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ZYME
ZYME has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ZYME
The primary concerns for ZYME are EPS Growth, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while ZYME is a turnaround play — different risk/reward profiles.
ZYME carries more volatility with a beta of 1.20 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 20/100). ZYME offers better value entry with a 29.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Zymeworks Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?